UNSPSC 51282310: Azithromycin dihydrate

This classification denotes a macrolide antibiotic with the molecular formula C38H72N2O12.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5FD1131I7S, chemically known as 11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-trihydroxy-13-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one but more generally known as azithromycin dihydrate, which bears US NIH Compound Identifier 55185.

UNSPSC 51282310 Azithromycin dihydrate, a Commodity code, nominally addresses a single active pharmaceutical ingredient, but recent state and local procurement activity under this code shows minimal alignment with the specific drug named. The recent opportunities tagged to this code—a naloxone and drug deactivation systems purchase, a Texas pharmacy benefit program RFI, Tampa fire rescue medical supplies, and a Minnesota multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products—span public health procurement across emergency response, pharmacy benefit management, emergency services, and multi-state bulk pharmaceutical distribution. None of these solicitations explicitly reference azithromycin or any single named active ingredient; instead, they reflect the broader landscape of state and local pharmaceutical and medical supply acquisition. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire and rescue services (City of Tampa Fire Department), and state purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance).

Recent geographic activity centers on Florida, Texas, Minnesota, and Oregon, with the Tampa and Seminole County solicitations in the Southeast, the Texas HHS RFI drawing vendors statewide, and the MMCAP cooperative serving multiple state jurisdictions. The most concrete recent opportunity is the City of Tampa's IFB 26P00145 for medical and first aid supplies due March 13, 2026, with an estimated contract value of $700,000 and a sheltered-market set-aside for certified Small Local Business Enterprises offering a 5 percent bid discount. The Minnesota MMCAP RFP (S1070000015802) for generic pharmaceuticals and OTC products, due March 26, 2026, represents large-scale multi-state cooperative procurement with incumbent and new vendor participation, requiring NDC-specific pricing and wholesaler relationships. The Texas HHS RFI (HHS0017013) from April 2026 signals emerging state interest in direct-to-manufacturer pharmacy contracting models. This code shows little activity specifically targeting azithromycin procurement and may warrant verification of code-to-opportunity alignment before pursuit.